ERBB2 and breast carcinoma: Although HER2 underexpression and ultralow expression do not significantly contribute to the proliferation and differentiation of breast cancer cells, there is increasing evidence that targeting HER2 therapy can still provide clinical benefits in cases of underexpression and ultralow expression.